Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort

Table 4 Univariate and multivariable logistic regression analysis of factors predicting a persistent compared to a non-persistent disease evolution (monophasic and polyphasic were combined to one category)

Potential predictors	Persistent disease evolution group^a (% of patients)	Crude odds ratio (95% CI) N = 65	P-value	Adjusted odds ratio (95% CI) N = 65	P-value
Age at disease onset < 6 years (vs. age ≥ 6 years,ref.categ.)	72.2%	3.68 (1.30 – 10.40)	0.014	2.57 (0.70 – 9.46)	0.155
Arthritis at 12 months (vs. no arthritis, ref. categ.)	44.5%	2.11 (1.24 – 3.6)	0.006	4.45 (0.58 – 34.20)	0.151
bDMARD use	94.4%	5.41 (1.03 – 28.46)	0.046	1.35 (0.15 – 11.85)	0.785
sDMARD use	83%	15.8 (4.68 – 53.79)	< 0.001	5.28 (1.39 – 20.01)	0.014
PGA ≥ 3 at 12 months	73.7%	0.02 (0.002 – 0.21)	< 0.001	^b
CRP > 10 mg/L at 12 months	47.2%	19.1 (3.54 – 103.16)	< 0.001	^b

Median (25–75 percentiles) if not otherwise specified
bDMARD Biologic disease modifying anti-rheumatic drugs, sDMARD Synthetic disease modifying anti-rheumatic drugs, PGA Physician’s Global Assessment, CRP C-reactive protein
^a Persistent disease evolution group; persistent disease during 24 months
^b Not included in the final model

ISSN: 1546-0096